1. Home
  2. UCL vs SNTI Comparison

UCL vs SNTI Comparison

Compare UCL & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

BUY

Current Price

$0.24

Market Cap

10.6M

ML Signal

BUY

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.22

Market Cap

10.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCL
SNTI
Founded
2014
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
10.4M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
UCL
SNTI
Price
$0.24
$0.22
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $13.50
AVG Volume (30 Days)
★ 372.5K
332.4K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.31
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$127.27
Revenue Next Year
$15.99
N/A
P/E Ratio
$13.72
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.22
$0.24
52 Week High
$2.63
$6.21

Technical Indicators

Market Signals
Indicator
UCL
SNTI
Relative Strength Index (RSI) 25.84 45.95
Support Level N/A N/A
Resistance Level $0.44 $0.90
Average True Range (ATR) 0.02 0.15
MACD 0.00 0.09
Stochastic Oscillator 10.37 0.18

Price Performance

Historical Comparison
UCL
SNTI

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: